scholarly journals Analysis of the gut microbiome of Japanese inflammatory bowel disease patients

2019 ◽  
Author(s):  
Yuto Fukui ◽  
Hitoshi Nakajima ◽  
Kotaro Aoki ◽  
Ohmori Toshihide ◽  
Kazuhiro Tateda ◽  
...  
Keyword(s):  
Inflammatory Bowel Disease ◽  
Bowel Disease ◽  
Gut Microbiome ◽  
Illumina Miseq ◽  
Japanese Patients ◽  
Amplicon Sequencing ◽  
Cross Sectional Study ◽  
Healthy Individuals ◽  
Cross Sectional ◽  
Inflammatory Bowel

Abstract Background Gut microbiome dysbiosis has been reported in patients with inflammatory bowel disease (IBD). However, gut microbiome of healthy Japanese individuals differs from that of other populations and gut microbiome of Japanese IBD patients has not been well characterized. We conducted a cross-sectional study to characterize the gut microbiome of Japanese patients with Crohn’s disease (CD) and ulcerative colitis (UC). Methods Two-hundred and eighty-four IBD patients (39 CD patients and 245 UC patients) and 31 healthy participants were enrolled. Gut microbiome was analyzed by 16S rRNA amplicon sequencing using Illumina Miseq. Results Significant differences were observed among the gut microbiome of CD patients, UC patients and healthy individuals. Species richness and evenness were significantly lower in patients with active IBD than in healthy individuals. At the genus level, Bifidobacterium was most abundant genera in all three groups. Pathogenic obligate anaerobes such as Prevotella and Veillonella were increased and commensal bacteria such as Ruminococcus was decreased in IBD patients compared with healthy individuals. Conclusions CD patients and UC patients showed unique patterns of gut microbiome dysbiosis. Patients with active IBD had severe dysbiotic changes. However, characteristic features of the gut microbiome of Japanese individuals, such as high abundance of the genus Bifidobacterium, were maintained in IBD patients.

Prospective, Observational, Cross-Sectional Study of Intestinal Infections among Acutely Active Inflammatory Bowel Disease Patients

Digestion ◽  
2009 ◽  
Vol 80 (1) ◽  
pp. 25-29 ◽  
Author(s):  
Mercè Navarro-Llavat ◽  
Eugeni Domènech ◽  
Isabel Bernal ◽  
Jordi Sánchez-Delgado ◽  
José M. Manterola ◽  
...  
Keyword(s):  
Inflammatory Bowel Disease ◽  
Bowel Disease ◽  
Cross Sectional Study ◽  
Sectional Study ◽  
Cross Sectional ◽  
Active Inflammatory Bowel Disease ◽  
Intestinal Infections ◽  
Inflammatory Bowel

scholarly journals COVID-19 Vaccine Hesitancy among Patients with Inflammatory Bowel Disease Receiving Biologic Therapies in Kuwait: A Cross-Sectional Study

Vaccines ◽  
2021 ◽  
Vol 10 (1) ◽  
pp. 55
Author(s):  
Mohammad Shehab ◽  
Yasmin Zurba ◽  
Ali Al Abdulsalam ◽  
Ahmad Alfadhli ◽  
Sara Elouali
Keyword(s):  
Ulcerative Colitis ◽  
Inflammatory Bowel Disease ◽  
Bowel Disease ◽  
Cross Sectional Study ◽  
Biologic Therapies ◽  
Sectional Study ◽  
Cross Sectional ◽  
Female Patients ◽  
Inflammatory Bowel ◽  
To Receive

Background: COVID-19 vaccinations have been shown to be effective in reducing risk of severe infection, hospitalization, and death. They have also been shown to be safe and effective in patients with inflammatory bowel disease (IBD) who are receiving biologic therapies. In this study, we aimed to evaluate the prevalence of vaccination among patients receiving biologic therapies for IBD. Methods: A single-center prospective cross-sectional study conducted at a tertiary care inflammatory bowel disease center in Kuwait. Data from patients with inflammatory bowel disease (IBD) who attended the gastroenterology infusion clinic from 1 June 2021 until 31 October 2021 were retrieved. Patients who received infliximab or vedolizumab at least six weeks before recruitment were included. The primary outcome was prevalence of COVID-19 vaccination. The secondary outcome was to assess whether prevalence of COVID-19 vaccination differed based on sex, age, type of biologic therapy and nationality. Results: The total number of inflammatory bowel disease (IBD) patients enrolled in the study was 280 (56.0% male and 44.0% female). Of the total, 112 (40.0%) patients were diagnosed with ulcerative colitis and 168 (60.0%) with Crohn’s disease. The number of ulcerative colitis patients who were vaccinated was 49 (43.8%) and the number of Crohn’s disease patients who were vaccinated was 68 (40.5%). The median age was 33.2 years and BMI was 24.8 kg/m2. With respect to the total number of patients, 117 (41.8%) were vaccinated with either BNT162b2 or ChAdOx1 nCoV-19 and 163 (58.2%) were not vaccinated. Female patients were more likely to receive the vaccine compared to male patients (83.0% vs. 63.8%, p < 0.001). In addition, patients above the age 50 were more likely to receive the vaccine than patients below the age of 50 (95.6% vs. 31.2% p < 0.001). Expatriates were more likely to receive the vaccine than citizens (84.8% vs. 25.0%, p < 0.001). There was no statistical difference between patients on infliximab and vedolizumab with regard to prevalence of vaccination (40.0% vs 48.0%, p = 0.34). Conclusion: The overall prevalence of COVID-19 vaccination among patients with inflammatory bowel disease (IBD) on biologic therapies was lower than that of the general population and world health organization (WHO) recom-mendation. Female patients, patients above the age of 50, and expatriates were more likely to receive the vaccine. Physicians should reinforce the safety and efficacy of COVID-19 vaccines among patients, especially IBD patients on biologic therapies, who express hesitancy towards them.

scholarly journals Psychologic stress and disease activity in patients with inflammatory bowel disease: A multicenter cross-sectional study

PLoS ONE ◽  
2020 ◽  
Vol 15 (5) ◽  
pp. e0233365 ◽  
Author(s):  
Manabu Araki ◽  
Shinichiro Shinzaki ◽  
Takuya Yamada ◽  
Shoko Arimitsu ◽  
Masato Komori ◽  
...  
Keyword(s):  
Inflammatory Bowel Disease ◽  
Disease Activity ◽  
Bowel Disease ◽  
Cross Sectional Study ◽  
Sectional Study ◽  
Cross Sectional ◽  
Psychologic Stress ◽  
Inflammatory Bowel

scholarly journals A Cross-Sectional Study on Malnutrition in Inflammatory Bowel Disease: Is There a Difference Based on Pediatric or Adult Age Grouping?

2019 ◽  
Vol 25 (8) ◽  
pp. 1428-1441 ◽  
Author(s):  
Valérie Marcil ◽  
Emile Levy ◽  
Devendra Amre ◽  
Alain Bitton ◽  
Ana Maria Guilhon de Araújo Sant’Anna ◽  
...  
Keyword(s):  
Inflammatory Bowel Disease ◽  
Bowel Disease ◽  
Vitamin B12 Deficiency ◽  
Cross Sectional Study ◽  
Additional Risk Factor ◽  
Cross Sectional ◽  
Adult Age ◽  
Reactive Protein ◽  
B12 Deficiency ◽  
Inflammatory Bowel

Abstract Background Malnutrition, commonly observed in inflammatory bowel disease (IBD), is associated with increased morbidity and mortality and is attributed to multiple causes. The added energy costs of growth in the child and adolescent with IBD are an additional risk factor. Methods The aim of the study was to perform a cross-sectional comparison of nutritional parameters in IBD between pediatric and adult cases. Results We found that prevalence of undernutrition (low body mass index) and hypoalbuminemia was not different in pediatric, compared with adult patients. Anemia and iron deficiency were more often observed in pediatric subjects, compared with adults (59.1% vs 36.9%, respectively, P < 0.0001; and 37.9% vs 25.3%, P < 0.002). Vitamin B12 deficiency was significantly less common in the pediatric than in the adult group (5.4% vs 19.4%, P < 0.0001). Elevated C-reactive protein was more frequent in pediatric compared with adult cases (49.8% vs 38.4%, P < 0.01). Conclusions Patients with active Crohn’s disease were more likely to be undernourished in both pediatric and adult populations. In both groups, predicators of undernutrition included low albumin levels (odds ratio [OR], 2.53; P < 0.006) and active disease (OR, 1.99; P < 0.03). Our results call for close surveillance of nutritional status for IBD patients, regardless of age.

Sign in / Sign up

Export Citation Format

Share Document